Sonrotoclax clinical trials
Sonrotoclax is named as an intervention in 28 current clinical trials in our China, USA, Italy, UK, Germany, France, Spain, Australia, Brazil, Poland, Canada, South Korea, Israel, Austria, Netherlands, Sweden, Czechia, Japan, Turkey, Belgium, Denmark, Ireland and Singapore registers. 15 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is BeOne Medicines (12). The most-studied condition is Chronic Lymphocytic Leukemia.
Where Sonrotoclax is approved
All regulators →Of the three regulators tracked here, the first to approve Sonrotoclax was the US, on 13 May 2026.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Sonrotoclax patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Sonrotoclax, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 29 Apr 2039 (US 11420968).
- Latest patent on the drug substance itself: 29 Apr 2039 (US 11420968).
- Exclusivity NCE: New chemical entity, until 13 May 2031.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Sonrotoclax works
All drug targets →- B-cell chronic lymphocytic leukemiaPhase 3
- Mantle cell lymphomaPhase 3
- AL amyloidosisPhase 2
- Richter transformationPhase 2
- Waldenstrom macroglobulinemiaPhase 2
- Acute myeloid leukemiaPhase 2
- Follicular lymphomaPhase 2
- Myelodysplastic syndromePhase 1/2
- Plasma cell myelomaPhase 1/2
- Acute myeloid leukemia by FAB classificationPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314951, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13354, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Sonrotoclax
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Sonrotoclax
28 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Sonrotoclax
34 conditionsAll 34 conditions
| Condition (as registered) | Trials |
|---|---|
| Chronic Lymphocytic Leukemia | 5 |
| Mantle Cell Lymphoma | 5 |
| Acute Myeloid Leukemia | 3 |
| Small Lymphocytic Lymphoma | 2 |
| Waldenstrom Macroglobulinemia | 2 |
| CLL | 2 |
| MCL | 2 |
| Lymphoma | 2 |
| B Cell Lymphoma | 1 |
| Refractory Mantle Cell Lymphoma (MCL) | 1 |
| Relapsed Mantle Cell Lymphoma | 1 |
| Mature B-Cell Malignancies | 1 |
| Waldenstrom's Macroglobulinemia Recurrent | 1 |
| Waldenstrom's Macroglobulinemia Refractory | 1 |
| Relapsed/Refractory Multiple Myeloma | 1 |
| Myelodysplastic Syndromes | 1 |
| Myelodysplastic/Myeloproliferative Neoplasm | 1 |
| B-cell Malignancy | 1 |
| Relapsed Cancer | 1 |
| Refractory Cancer | 1 |
| B-cell Lymphoma | 1 |
| Myelodysplastic Syndromes, High Risk | 1 |
| AL Amyloidosis (AL) | 1 |
| t(11;14) Positive | 1 |
| Leukemia | 1 |
| Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 |
| Large B-cell Lymphoma | 1 |
| Multiple Myeloma (MM) | 1 |
| Newly Diagnosed Mixed Phenotype Acute Leukemia | 1 |
| CLL / SLL | 1 |
| Large B-Cell Lymphoma (LBCL) | 1 |
| High-grade B-cell Lymphoma | 1 |
| Richter Transformation | 1 |
| Small Lymphocytic Leukemia | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Sonrotoclax trials
How many clinical trials are testing Sonrotoclax?
28 current trials in our China, USA, Italy, UK, Germany, France, Spain, Australia, Brazil, Poland, Canada, South Korea, Israel, Austria, Netherlands, Sweden, Czechia, Japan, Turkey, Belgium, Denmark, Ireland and Singapore registers name Sonrotoclax (also registered as BGB-11417) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Sonrotoclax trials recruiting patients?
Yes. 15 of the 28 trials are recruiting: 11 with sites in China, 7 with sites in USA, 6 with sites in Italy, 6 with sites in UK, 7 with sites in Germany, 6 with sites in France, 5 with sites in Spain, 7 with sites in Australia, 6 with sites in Brazil, 4 with sites in Poland, 4 with sites in Canada, 5 with sites in South Korea, 3 with sites in Israel, 3 with sites in Austria, 2 with sites in Netherlands, 2 with sites in Sweden, 2 with sites in Czechia, 2 with sites in Japan, 1 with sites in Turkey, 1 with sites in Belgium, 2 with sites in Denmark, 1 with sites in Ireland and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Sonrotoclax clinical trials?
BeOne Medicines (12), Ruijin Hospital (2), The First Affiliated Hospital of Soochow University (2) and Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1), among 15 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Sonrotoclax clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sonrotoclax works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sonrotoclax works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sonrotoclax (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.